The 2017 Industrial Strategy White Paper is the UK Government’s plan to boost productivity. The pharmaceutical industry was recognised as a key sector.
As a key sector, Professor Sir John Bell was asked to present to Government a Life Sciences Industrial Strategy.
The Life Sciences Industrial Strategy includes recommendations on how the Government can maintain the UK's existing strength in life sciences and increase the pace of economic growth in this sector.
Its key recommendations include:
Setting an ambition for the UK to be in the top quartile of comparable countries when it comes to the patients getting the most innovative medicines
The ABPI was a member of the Life Sciences Industrial Strategy Board and helped to develop this Strategy.
As a result of these, the Government published a sector deal – to help ensure new pioneering treatments and medical technologies are produced in the UK, improving patient lives and driving economic growth.
PwC published a new report in March 2017, The economic contribution of the UK Life Science industry, to determine the value added to the UK economy by the life sciences sector.
The UK biopharmaceutical industry has: